Earlier to Locus Pharmaceuticals, Dr. Freedman was at Merck Research Labs where he held various positions of increasing responsibility in Clinical Pharmacology, Clinical Oncology, and Experimental Medicine, conducting and supervising drug development programs, including those dealing with RNA interference modalities.
Dr. Freedman received M.D. and Ph.D. degrees from Tufts University and trained in Medicine and Hematology-Oncology at University of California, San Francisco and Harvard, respectively. Prior to join the industry, Dr. Freedman conducted research at the Beth Israel Deaconess Medical Center at Harvard University and also served as an Adjunct Assistant Professor of Medicine at University of Pennsylvania Medical Center.
We are pleased to welcome Dr. Freedman to the OPKO team, said Phillip Frost, chairman and CEO of OPKO. Dr. Freedman brings years of drug research and development experience to OPKO that spans the entire development process.
OPKO is a healthcare company presently with an emphasis in the field of ophthalmology.
